Cero Therapeutics Officer YK Bioventures Opportunities GP I, LLC Sold 3,250,000 Shares

SEC Track

15 Nov 2024

Cero Therapeutics Holdings, Inc. (Ticker: CERO) Officer YK Bioventures Opportunities GP I, LLC sold 3,250,000 shares of common stock on October 10, 2024, at an average price of approximately $0.10 per share. Following this transaction, their indirect ownership stands at 22,620,783 shares. This sell-off by a senior officer may indicate a cautious outlook on the company's short-term prospects, and investors should consider this along with other market information before making investment decisions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/1179912983"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179912983\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1179912983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 09:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179912983","market":"us","top_or_hot":-1,"title":"Cero Therapeutics Officer YK Bioventures Opportunities GP I, LLC Sold 3,250,000 Shares","media":"SEC Track","content":"Cero Therapeutics Holdings, Inc. (Ticker: CERO) Officer YK Bioventures Opportunities GP I, LLC sold 3,250,000 shares of common stock on October 10, 2024, at an average price of approximately $0.10 per share. Following this transaction, their indirect ownership stands at 22,620,783 shares. This sell-off by a senior officer may indicate a cautious outlook on the company's short-term prospects, and investors should consider this along with other market information before making investment decisions.","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cero Therapeutics Officer YK Bioventures Opportunities GP I, LLC Sold 3,250,000 Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCero Therapeutics Officer YK Bioventures Opportunities GP I, LLC Sold 3,250,000 Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1033292654\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SEC Track </p>\n<p class=\"h-time\">2024-11-15 09:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\nCero Therapeutics Holdings, Inc. (Ticker: CERO) Officer YK Bioventures Opportunities GP I, LLC sold 3,250,000 shares of common stock on October 10, 2024, at an average price of approximately $0.10 per share. Following this transaction, their indirect ownership stands at 22,620,783 shares. This sell-off by a senior officer may indicate a cautious outlook on the company's short-term prospects, and investors should consider this along with other market information before making investment decisions.\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CERO","symbol_name":"CERo Therapeutics Holdings, Inc.","start_time":0,"source_url":"","article_id":"1179912983","we_media_id":"1033292654","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179912983","pubTimestamp":1731633349,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SEC Track","introduction":"Stay Updated with Major Announcements","home_visible":1,"id":"1033292654","head_image":"https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5"},"summary":"Cero Therapeutics Holdings, Inc.  Officer YK Bioventures Opportunities GP I, LLC sold 3,250,000 shares of common stock on October 10, 2024, at an average price of approximately $0.10 per share. Following this transaction, their indirect ownership stands at 22,620,783 shares. This sell-off by a senior officer may indicate a cautious outlook on the company's short-term prospects, and investors should consider this along with other market information before making investment decisions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CERO":"CERo Therapeutics Holdings, Inc."},"translate_title":"Cero Therapeutics官员YK Bioventures Opportunities GP I,LLC出售3,250,000股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERO":1},"content_text":"Cero Therapeutics Holdings, Inc. (Ticker: CERO) Officer YK Bioventures Opportunities GP I, LLC sold 3,250,000 shares of common stock on October 10, 2024, at an average price of approximately $0.10 per share. Following this transaction, their indirect ownership stands at 22,620,783 shares. This sell-off by a senior officer may indicate a cautious outlook on the company's short-term prospects, and investors should consider this along with other market information before making investment decisions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"insiderTrades","news_rank":0,"symbols":[],"gpt_button":1}}}